Based on the synergy between TET2 to IL-2/STAT5A signaling (Fig. 6), we further examined whether VC enhanced the efficacy of anti-PD-L1 and IL-2 combination therapy, which is a potentially promising candidate for cancer therapy40,41. Here, IL2 is linked to cancer.